

COMPANY ANNOUNCEMENT

American Thoracic Society (ATS) accepts KarmelSonix Abstracts for presentation at Annual Meeting

- **Six abstracts to be presented at the San-Diego Annual Meeting of the ATS in May 2009**
- **Abstracts are the outcome of the KarmelSonix clinical studies program**
- **Mr Bill Ross, a past CEO of Viasys (now Cardinal Health) joins KarmelSonix Advisory Committee.**

10th February 2009 : The Directors of KarmelSonix Ltd (KSX or the Company) are pleased to announce that the American Thoracic Society has accepted for presentation all six submitted abstracts resulting from the Company’s clinical studies program. The presentations will take place in Thematic Poster Sessions during the forthcoming annual meeting of the Society in San-Diego, May 2009. The ATS Annual Convention is the largest Pulmonology and Intensive Care meeting in the world with over 16,000 participants from the US (60%) and the rest of the world (40%). Below are the titles of each of the presentations, institution and main conclusion:

- **Validation of an Automatic Wheeze Detector.** (KarmelSonix Israel)
 - *Conclusion:* The Automatic Wheeze Detector accurately detects wheezing in realistic clinical environments, including those that are inherently noisy.
- **Simulated Cough-Based Database for Cough-Counting Algorithm Validation** (KarmelSonix Israel).
 - *Conclusion:* The database created in these recordings may be useful in a validation process of the automatic cough counting application, and may provide a future standard for validating similar devices.
- **Airway Monitoring during Bronchodilation Using Acoustic Transmission Methods** (Alfred Hospital, Melbourne, AU).
 - *Conclusion:* The study results show that broncho-dilator medication increased transmission and did so more in those patients where the spirometric indices responded the greatest.
- **Wheeze Monitoring in Non-Asthmatic Pediatric Population** (Bnei Zion Medical Center, Haifa, Israel)
 - *Conclusion:* Patients who have normal lungs have very low Wz% (Wheeze Rates).

“Wheeze Rate – A New Paradigm in Asthma Management”

- **Wheeze Monitoring of Severe Asthmatics in the Emergency Setting - The “Silent Lung” Phenomenon** (Carmel Medical Center, Haifa, Israel)
 - *Conclusion:* Quantitative wheeze rate monitoring may be useful in assessing and documenting silent lung and dynamic wheeze activity in severe asthma.
- **Continuous Wheeze Monitoring during Bronchodilator Administration in Pediatric Asthma** (Carmel Medical Center, Haifa, Israel)
 - *Conclusion:* Wheeze monitoring clearly documented reversibility of broncho-constriction in part of these patients, thereby confirming the diagnosis of asthma.

The directors also wish to welcome **Mr William (Bill) Ross** as a new member of KarmelSonix’ Advisory Committee. Mr Ross, who was previously the CEO of Viasys (now Cardinal Health) has vast experience in bringing science-based devices to the medical markets with special background in positioning of devices for the ICU, PFT lab and Sleep Labs.

Mr. Ross will join the current team consisting of **Prof. Simon Godfrey (Chairman), Prof. Lynn Taussig and Prof Lew Smith.**

Mr. Ross commented that he strongly believes that the acoustic technology in general will make a substantial impact on how asthma is managed, but in particular he predicts that the Wheezometer will be the driving force behind this paradigm shift all the way to the patient home.

For additional information please contact:

Mr. Peter Marks, Chairman,	+61 (0)3 9824 8166	Peter@karmelsonix.com
Dr. Nathan Intrator, KSI CEO	+972 544 650 365	Nathan@karmelsonix.com
Prof. Noam Gavriely, CMO	+972 544 661 337	Noam@karmelsonix.com
Dr Henry Pinskiel, Director	+ 61 400 313 732	Henry@karmelsonix.com

KarmelSonix Ltd. focuses on supplying innovative non-invasive acoustic tools for disease management of asthma and related pulmonary disorders. Asthma affects 6-16% of the population in developed countries with a cost exceeding \$US15 billion in the US alone.

Acoustic Asthma Management is a breakthrough in monitoring of the asthmatic patient of all ages, including the very young, very old and others who cannot perform currently available tests. The technology that comes from extensive R&D and clinical validation in the US, Israel and Australia, facilitate continuous monitoring of patients at home, in the ICU and even during sleep. The company is focused on early commercialization of its products with special emphasis on the European and North American markets.

“Wheeze Rate – A New Paradigm in Asthma Management”